A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve Its Effectivess on Neuronal Aging
Laboratory studyOther animalsWith lipoic acid and vitamin D3 (tested with a proprietary PEA formulation, FM-LipoMatrix)
This study tested palmitoylethanolamide together with lipoic acid and vitamin D3 (tested with a proprietary PEA formulation, FM-LipoMatrix). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Intestinal barrier model and primary astrocyte cell cultures
- Dose used in the study
- Micronised PEA, FM-LipoMatrix PEA, or FM-LipoMatrix PEA plus lipoic acid and vitamin D3; concentrations not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Intestinal bioavailability; astrocyte cell viability, reactive oxygen species and nitric oxide production, NF-kB activity, MAPK, p53 and PPAR-alpha activity; cannabinoid and estrogen receptor levels by western blot
What the authors reported
The FM-LipoMatrix PEA formulation with lipoic acid and vitamin D3 showed better absorption than the other formulations, predicting higher plasma levels. This combination reduced ROS and NO production in astrocytes and was linked with cannabinoid and estrogen receptor interactions that lowered neuroinflammatory markers.
Limits of this study
A cell-culture and intestinal-barrier model study; it cannot show effect in people. The authors declare no conflict of interest; two authors co-founded the company noivita srls but report no commercial interest in the products studied.
Source
PubMed 32708932 · doi:10.3390/brainsci10070457
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.